Brief: Herantis Pharma H2 Net loss at EUR 136,700

Herantis Pharma Oyj

02/03/2018 07:06

March 2 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * ‍HERANTIS DOES NOT EXPECT ESSENTIAL REVENUES IN 2018​
    * ‍CONTINUES TO INVEST IN ITS ONGOING DEVELOPMENT PROGRAMS IN SECONDARY LYMPHEDEMA AND
PARKINSON'S
DISEASE​
    * ‍MAIN OBJECTIVES FOR 2018 ARE LAUNCHING A PHASE 2 CLINICAL STUDY WITH COMPANY'S DRUG
CANDIDATE
LYMFACTIN®​
    * ‍MAIN OBJECTIVES FOR 2018 ARE COMPLETING PATIENT RECRUITMENT IN PHASE 1-2 CLINICAL STUDY
WITH
CDNF​
    * ‍DID NOT HAVE ESSENTIAL REVENUES IN 2017 OR IN CORRESPONDING PERIOD IN PREVIOUS YEAR​
    * H2 NET LOSS EUR 136,700 VERSUS LOSS EUR 1.8 MILLION YEAR AGO
    * PROPOSES ‍THAT NO DIVIDEND SHALL BE PAID FOR FINANCIAL PERIOD JANUARY 1-DECEMBER 31,
2017.​

Source text for Eikon:  ID:nGNE5HjPKH 
Further company coverage:  HRTIS.HE 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))